Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Licenses Gene for Hereditary Breast, Ovarian Cancers

NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Wednesday that it has obtained an exclusive license to the RAD51C gene, which has been associated with an increased risk for hereditary breast and ovarian cancers.

The license from a consortium of German researchers gives Myriad the exclusive global rights, with co-exclusive rights in Germany, to provide commercial testing for the gene.

RAD51C was originally identified as a susceptibility gene for hereditary breast and ovarian cancers by researchers from the German Consortium for Hereditary Breast and Ovarian Cancer collaborating with pediatric hematologists and basic scientists primarily from the universities of Cologne, Dusseldorf, and Munich.

Researchers from those universities previously reported that mutations in the RAD51C gene were found "exclusively within 480 pedigrees with the occurrence of both breast and ovarian tumors … and not in 620 pedigrees with breast cancer only or in 2,912 healthy German controls," they said in the abstract of a study published in April 2010 in Nature Genetics.